MX2020009309A - Composiciones de cartirina y métodos para su uso. - Google Patents

Composiciones de cartirina y métodos para su uso.

Info

Publication number
MX2020009309A
MX2020009309A MX2020009309A MX2020009309A MX2020009309A MX 2020009309 A MX2020009309 A MX 2020009309A MX 2020009309 A MX2020009309 A MX 2020009309A MX 2020009309 A MX2020009309 A MX 2020009309A MX 2020009309 A MX2020009309 A MX 2020009309A
Authority
MX
Mexico
Prior art keywords
cartyrins
methods
cartyrin
disclosure
compositions
Prior art date
Application number
MX2020009309A
Other languages
English (en)
Inventor
Devon Shedlock
Eric Ostertag
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of MX2020009309A publication Critical patent/MX2020009309A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Abstract

Se describen receptores de antígenos quiméricos de Centirina (CARTirinas), transposones de CARTirina que codifican los CARTirinas de la divulgación, células modificadas para expresar los CARTirinas de la divulgación, así como también métodos para preparar y métodos para usar los mismos en terapia celular adoptiva. En modalidades preferidas, los CARTirinas de la divulgación específicamente se unen a una secuencia del antígeno de membrana específico de próstata (PSMA).
MX2020009309A 2018-03-07 2019-03-07 Composiciones de cartirina y métodos para su uso. MX2020009309A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862639978P 2018-03-07 2018-03-07
US201862745151P 2018-10-12 2018-10-12
US201862783140P 2018-12-20 2018-12-20
PCT/US2019/021224 WO2019173636A1 (en) 2018-03-07 2019-03-07 Cartyrin compositions and methods for use

Publications (1)

Publication Number Publication Date
MX2020009309A true MX2020009309A (es) 2021-01-08

Family

ID=66182630

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009309A MX2020009309A (es) 2018-03-07 2019-03-07 Composiciones de cartirina y métodos para su uso.

Country Status (14)

Country Link
US (1) US20210107993A1 (es)
EP (1) EP3762106A1 (es)
JP (1) JP7399866B2 (es)
KR (1) KR20200140270A (es)
CN (1) CN112601583A (es)
AU (1) AU2019230192A1 (es)
BR (1) BR112020018049A2 (es)
CA (1) CA3092947A1 (es)
IL (1) IL277079A (es)
MX (1) MX2020009309A (es)
SG (1) SG11202008659TA (es)
TW (1) TW202017592A (es)
WO (1) WO2019173636A1 (es)
ZA (1) ZA202005556B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2019243578A1 (en) * 2018-03-28 2020-10-15 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector T cells
WO2020051374A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
JP2022513507A (ja) 2018-12-20 2022-02-08 ポセイダ セラピューティクス，インコーポレイティド ナノトランスポゾン組成物および使用方法
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP2022547866A (ja) 2019-09-05 2022-11-16 ポセイダ セラピューティクス，インコーポレイティド 同種異系細胞組成物と使用方法
EP4041759A4 (en) * 2019-10-07 2023-12-20 Fate Therapeutics, Inc. IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL CULTURE AND USE THEREOF
WO2021127505A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
GB201919019D0 (en) * 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
US20230085945A1 (en) * 2020-02-25 2023-03-23 The Board Of Trustees Of The Leland Stanford Junior University Orthogonal safety switches to eliminate genetically engineered cells
AU2021230361A1 (en) 2020-03-04 2022-09-08 Poseida Therapeutics, Inc. Compositions and methods for the treatment of Metabolic Liver Disorders
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN111458517B (zh) * 2020-03-13 2022-08-16 深圳大学 Selenof作为阿尔茨海默病药物靶点的应用
JP2023519346A (ja) 2020-03-27 2023-05-10 メンドゥス・ベスローテン・フェンノートシャップ 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
CN112480242B (zh) * 2020-12-04 2023-06-06 中国人民解放军陆军军医大学 Spink7蛋白在制备预防和/或治疗溃疡性结肠炎的药物中的应用
CN112574291B (zh) * 2020-12-14 2022-10-21 上海交通大学 一种生物活性肽shrkfsaprhgslgflpr及其制备方法和应用
CN112625142B (zh) * 2021-02-03 2023-05-09 郑州大学第一附属医院 Cxcl9修饰的car-t结构及其应用
WO2022170184A1 (en) * 2021-02-05 2022-08-11 University Of Cincinnati Lipocalin 10 as a therapeutic agent for inflammation-induced organ dysfunction
WO2022182792A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
EP4301863A1 (en) 2021-03-04 2024-01-10 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
JP2024513454A (ja) * 2021-04-07 2024-03-25 センチュリー セラピューティクス，インコーポレイテッド キメラ抗原受容体細胞のための人工細胞死／リポーター系ポリペプチドの組合せおよびその使用
CN117529333A (zh) 2021-04-16 2024-02-06 细胞基因公司 对先前进行过干细胞移植的患者的t细胞疗法
US20220339245A1 (en) * 2021-04-27 2022-10-27 Academia Sinica Methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
AU2022358729A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposases and uses thereof
CA3233506A1 (en) 2021-10-04 2023-04-13 Joseph S. LUCAS Transposon compositions and methods of use thereof
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
CN114716564B (zh) * 2021-12-20 2023-02-28 四川大学华西医院 基于sectm1构建的嵌合抗原受体免疫细胞制备及其应用
CN113999873B (zh) * 2021-12-31 2022-05-20 北京市疾病预防控制中心 一种基因修饰的非人动物的构建方法及其应用
CN114470225B (zh) * 2022-01-20 2023-09-12 苏州市立医院 一种重组人cdc5l融合蛋白水凝胶、制备方法及应用
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
WO2023152498A1 (en) 2022-02-09 2023-08-17 Horizon Discovery Limited Polynucleotides with selection markers
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
CN114573678B (zh) * 2022-03-11 2022-12-27 中山大学 一种Rheb蛋白激活剂及其应用
CN114644685B (zh) * 2022-04-07 2023-07-04 华中科技大学同济医学院附属协和医院 一种可拮抗hnRNPK蛋白RNA结合活性的多肽HIP-15及其应用
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN114748498A (zh) * 2022-05-13 2022-07-15 南京大学 针对CBFβ的shRNA在制备治疗结直肠癌药物中的应用
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023235897A2 (en) * 2022-06-03 2023-12-07 Oyster Point Pharma. Inc. Aav vector encoding diamine oxidase and uses thereof
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use
WO2024073440A1 (en) 2022-09-27 2024-04-04 Genentech, Inc. Inhibition of genotoxic stress to improve t cell engineering
CN116574193A (zh) * 2023-05-10 2023-08-11 浙江大学 一种可抑制肿瘤坏死因子的简化巨球蛋白及合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
AU757153B2 (en) 1997-09-29 2003-02-06 Novartis Ag Stabilized preparations for use in metered dose inhalers
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7910697B2 (en) * 2004-10-21 2011-03-22 Ono Pharmaceutical Co., Ltd. Use of immunesuppressant receptor
US10233454B2 (en) 2014-04-09 2019-03-19 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
EA201792441A2 (ru) * 2015-05-06 2018-06-29 Янссен Байотек, Инк. Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
WO2016179518A2 (en) * 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
GB201602563D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
BR112019000683A2 (pt) * 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
MX2019006374A (es) * 2016-12-02 2019-09-11 Univ Southern California Receptores inmunes sinteticos y metodos de usos de ellos.

Also Published As

Publication number Publication date
KR20200140270A (ko) 2020-12-15
SG11202008659TA (en) 2020-10-29
US20210107993A1 (en) 2021-04-15
IL277079A (en) 2020-10-29
WO2019173636A1 (en) 2019-09-12
WO2019173636A9 (en) 2020-11-05
CA3092947A1 (en) 2019-09-12
BR112020018049A2 (pt) 2020-12-29
AU2019230192A1 (en) 2020-10-08
RU2020132750A (ru) 2022-04-07
ZA202005556B (en) 2024-03-27
TW202017592A (zh) 2020-05-16
AU2019230192A2 (en) 2020-10-22
CN112601583A (zh) 2021-04-02
JP2021516958A (ja) 2021-07-15
EP3762106A1 (en) 2021-01-13
JP7399866B2 (ja) 2023-12-18

Similar Documents

Publication Publication Date Title
ZA202005556B (en) Cartyrin compositions and methods for use
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
MX2020006689A (es) Composiciones de vcar y metodos de uso.
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
MX2022003995A (es) Antigeno quimerico y receptores de celulas t y metodos de uso.
MX2022006568A (es) Agentes anti-cd20, agentes anti-cd22, y usos y combinaciones de los mismos con una celula que expresa un receptor de antigeno quimerico (car) de cd19.
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MX2019008346A (es) Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
PH12014502418A1 (en) Enhanced affinity t cell receptors and methods for making the same
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
GB2549632A8 (en) Fusion protein comprising three binding domains to 5T4 and CD3
PH12014501758B1 (en) Cd47 antibodies and methods of use thereof
CL2016002689A1 (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
MX2019003983A (es) Caspasas inducibles y metodos de uso.
MX2016011194A (es) Construcciones de expresion y metodos para seleccionar celulas huesped que expresan polipeptidos.